Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Journal of Medical Economics|November 9, 2016
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosisDuygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, et al.Journal of Medical Economics|December 29, 2015
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United StatesJosephine Mauskopf, Monica Fay, Ravi Iyer, et al.Multiple Sclerosis and Related Disorders|July 24, 2023
Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world dataLilyana Amezcua, Terrie Livingston, Brooke Hayward, et al.Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care ProgramsTerrie Livingston, Monica Fay, Ravi Iyer, et al.International Journal of MS Care|March 16, 2023
Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational AnalysisLeorah Freeman, Ashlea Lucas, Jia Zhou, et al.Journal of Managed Care & Specialty Pharmacy|March 2, 2015
Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective studyR Brett McQueen, Terrie Livingston, Timothy Vollmer, et al.Patient Preference and Adherence|July 28, 2018
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeksBarry Hendin, Robert T Naismith, Sibyl E Wray, et al.Multiple Sclerosis and Related Disorders|October 28, 2018
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the USDaniel Ontaneda, Jacqueline Nicholas, Matthew Carraro, et al.Frontiers in Neurology|December 18, 2023
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovationJiwon Oh, Laura Airas, Daniel Harrison, et al.International Journal of MS Care|September 6, 2021
Perceptions and Preferences Regarding Multiple Sclerosis Research Among Racial and Ethnic GroupsDaniela A Pimentel Maldonado, April Moreno, Mitzi J Williams, et al.Pageof 2